Cell line · CVCL_1115
CAMA-1
Cancer cell line, Homo sapiens. Breast adenocarcinoma. 60 papers.
4 sourcescell-lines-2026-11-14-0.1.0
Download JSON
Cite this record
ConductScience Library. CAMA-1. Cell lines, record CVCL_1115. Release cell-lines-2026-11-14-0.1.0, 14 Nov 2026. https://conductscience.org/library/cell-lines/CVCL_1115
On this page
Cell line
As Cellosaurus gives it.
- Name
- CAMA-1
- Accession
- CVCL_1115
- RRID
- RRID:CVCL_1115
- Synonyms
- Cama-1, CAMA1, CAMA
- Species
- Homo sapiens (Human)
- Sex
- Female
- Age at sampling
- 51Y
- Category
- Cancer cell line
- Diseases
- Breast adenocarcinoma (NCIt C5214)
- Derived from
- Pleural effusion (metastatic)
- Entry created
- 2012-04-04
- Entry updated
- 2025-04-10
Source Cellosaurus
Problems0
Cellosaurus records no problem for this cell line.
None in this release.
Papers60
| Paper | Journal | Year | How we know | Retracted | Source |
|---|---|---|---|---|---|
| The role of autoproteolysis and mitoribosomal proteins in the regulation of the mitochondrial LACTB tumor suppressor. | EMBO Rep | 2026 | Its Methods give the RRID and name the line | PubMed | |
| E3 Ubiquitin Ligase Mind Bomb 1 is a Novel Negative Regulator of Tumor-Suppressive BMP Signaling. | Cancer Res Commun | 2026 | Its Methods give the RRID and name the line | PubMed | |
| Targeted antibody-drug conjugates for rhabdomyosarcoma and other FGFR4-expressing cancers. | Cell Rep Med | 2026 | Its Methods give the RRID and name the line | PubMed | |
| CDK2 Inhibition Exerts RB-Independent Antitumor Activity in CDK4/6 Inhibitor-Resistant HR+/HER2- Breast Cancer. | Cancer Res | 2026 | Its Methods give the RRID and name the line | PubMed | |
| A convergent uPAR-positive tumor ecosystem creates broad vulnerability to CAR T cell therapy. | Cell | 2026 | Its Methods give the RRID and name the line | PubMed | |
| The Selective Estrogen Receptor Degrader ZN-c5 Has Broad Antitumor Activity in Wild-Type and Mutant ER-Positive Breast Cancer Models. | Mol Cancer Ther | 2026 | Its Methods give the RRID and name the line | PubMed | |
| Trastuzumab Deruxtecan Resistance via Loss of HER2 Expression and Binding. | Cancer Discov | 2026 | Its Methods give the RRID and name the line | PubMed | |
| Simulating cell-free chromatin using preclinical cancer models for liquid biopsy applications. | iScience | 2025 | Its Methods give the RRID and name the line | PubMed | |
| Therapeutic benefits of maintaining CDK4/6 inhibitors and incorporating CDK2 inhibitors beyond progression in breast cancer. | Elife | 2025 | Its Methods give the RRID and name the line | PubMed | |
| System analysis links SMARCD3 regulons to growth signaling and MEK inhibitor response in everolimus-resistant ER+ breast cancer cells. | Cell Rep Med | 2025 | Its Methods give the RRID and name the line | PubMed |
1 to 10 of 60
See all 60 papersRelatives1
| Relation | Cell line | Accession | Problem |
|---|---|---|---|
| Derived from it | CAMA-1/Cas9-hyg | CVCL_C9DC |
Source Cell lines
Cell banks2
| Cell bank | Catalog number | Status | Source |
|---|---|---|---|
| ATCC | HTB-21 | ATCC | |
| CancerTools | 161925 | CancerTools |
Data dates
The date of each source this release read.
Sources 4
- CellosaurusCC BY 4.0, with credit to Cellosaurus (SIB)
- PubMed Central's articlesTitles shown only for CC0, CC BY and public domain articles
- NLM's PMC Article DatasetsCourtesy of NLM, which does not endorse this database
- PubMedNLM's terms
Each source's terms
- CellosaurusCC BY 4.0. Cellosaurus's README: "we have chosen to apply the Creative Commons Attribution 4.0 International (CC BY 4.0) license to Cellosaurus (https://creativecommons.org/licenses/by/4.0/). This means that you are free to copy and redistribute Cellosaurus in any medium or format. You can remix, transform, and build upon Cellosaurus for any purpose, even commercially. You must give appropriate credit, provide a link to the license, and indicate if changes were made." Copyright (c) CALIPHO group, SIB Swiss Institute of Bioinformatics. Read on 14 Nov 2026 at https://ftp.expasy.org/databases/cellosaurus/README
- PubMed Central's articlesEach article's own license. Its words show only under CC0, CC BY or public domain
- NLM's PMC Article DatasetsNLM's PMC Article Datasets on AWS, https://registry.opendata.aws/ncbi-pmc. Its terms: users "acknowledge NLM as the source of the data in a clear and conspicuous manner", do not use the PubMed Central wordmark or the PMC logo, do not "indicate or imply that NLM/NIH/HHS has endorsed" a product, and "only distribute data that are licensed for redistribution". Each article keeps its own license: https://pmc.ncbi.nlm.nih.gov/about/copyright/
- PubMedNLM's terms
Cellosaurus, SIB Swiss Institute of Bioinformatics, https://www.cellosaurus.org, CC BY 4.0. Its problem notes are given in its own words.
For software
Read this cell line from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/cell-lines/v1/CVCL_1115
GET https://conductscience.org/api/cell-lines/v1/CVCL_1115/papers?page=2